WINNIPEG, MANITOBA--(MARKET WIRE)--Sep 20, 2007 -- Medicure Inc. (Toronto:MPH.TO - News)(AMEX:MCU - News), a cardiovascular focused biopharmaceutical company, today announced the completion of enrollment of 3,000 patients in its MEND-CABG II trial. This pivotal Phase 3 trial for registration is evaluating the Company’s FDA Fast Tracked product MC-1’s safety and cardioprotective efficacy in patients undergoing coronary artery bypass graft (CABG) surgery.
